• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aciphex (rabeprazole sodium)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aciphex (rabeprazole sodium)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    In February 2002, the indications for Aciphex were expanded to include the treatment of patients with symptomatic gastroesophageal reflux disease (GERD). Aciphex, a proton pump inhibitor, can now be used for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD.

    Individuals with symptomatic GERD often suffer from heartburn, belching and regurgitation (when digestive acid moves back up the esophagus). In contrast to those with erosive GERD, patients with symptomatic GERD do not have evidence of erosion to the esophagus. Heartburn, which affects over 60 million Americans on a monthly basis, is the most common symptom of symptomatic GERD.

    Prior to this new indication, Aciphex was approved for the healing of erosive GERD, the maintenance of healed erosive GERD, and the healing of duodenal ulcers. Aciphex is also used for the treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

    Clinical Results

    Two multicenter, double-blind, placebo-controlled trials evaluating Aciphex were conducted in the United States. The trials included 316 subjects with daytime and nighttime heartburn who did not have esophageal erosions. Subjects received either Aciphex 10 mg, Aciphex 20 mg or placebo, and they were given a diary to keep track of their GERD symptoms. Subjects returned for assessment at week two and four.

    Trials results demonstrated that the percentage of heartburn-free daytime and/or nighttime periods was significantly greater with Aciphex 20 mg than with placebo. Additionally, daily antacid consumption was significantly reduced with Aciphex versus placebo over four weeks of treatment.

    Side Effects

    Treatment with rabeprazole has been generally well tolerated in both short-term and long-term trials.

    In the two US trials, the most common adverse events potentially related to Aciphex 20 mg (and occurring at greater than 2% frequency) were abdominal pain, diarrhea and headache.

    Mechanism of Action

    Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion.

    In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. It inhibits acid transport in porcine gastric vesicles with a half-life of 90 seconds. (from Aciphex Prescribing Information)

    Additional Information

    Aciphex is referred to as Pariet outside of the United States. Aciphex was discovered and developed by Eisai, and it is co-marketed in the United States by Eisai and Janssen Pharmaceutica.

    For additional information on Aciphex, please visit the product web site at www.aciphex.com.

    Individuals interested in learning more about GERD can obtain information from the National Institute of Diabetes and Digestive and Kidney Diseases.

    Approval Date: 2002-02-01
    Company Name: Elan Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing